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Summary A phase I trial was conducted with lobaplatin (D-19466; 1,2-diamminomethyl-cyclobutane-
platinum (II)-lactate) i.v. bolus daily for 5 days every 4 weeks. After entering five patients toxicity appeared to
be related to renal function, therefore the individual dose (total dose 20-100 mg m2 over 5 days) of
lobaplatin was modified according to creatinine clearance (CRCL) and escalated in patients. Twenty-seven
patients with refractory solid tumours received 72 courses. Thrombocytopenia was dose-limiting, its degree
was related to dose and CRCL at time of drug administration. With a CRCL of 60-80mlmin-' the
maximum tolerated dose was 40mgm-2, with a CRCL of 81-100mlmin-' 70mgm-2, and with a
CRCL>100mlmin-' it was 85mgm-2. Platelet and leukocyte nadirs were observed around day 21. The
percentual platelet nadir (percentage of day 1 platelet count) correlated with CRCL at different dose levels and
could be described by 0.76 x CRCL (ml min-') - {1.45 x dose (mg m-2) + 43.38. This equation tested in 20
patients (28 courses) produced a correlation between observed and predicted percentual platelet nadir
(r = 0.82, P<O0.001). No renal function impairment occurred. Urinary excretion of platinum (by A.A.S.) was
estimated in six patients and revealed that 91.5% (s.e. ± 7.9) of the platinum dose was excreted within 4 h.
Responses (one PR, one CR) occurred in two patients with ovarian cancer (both pretreated with carboplatin
and cisplatin).
The recommended dose of lobaplatin i.v. bolus daily for 5 days for phase II studies depends on renal
function, namely 30mgm-2 at CRCL 60-80mlmin-'; 55mgm-2 at CRCL 81 -00 mlmin-'; 70mgm-2 at
CRCL> 100 ml min-
Cis-Diamminedichloro-platinum (II) (cisplatin) has had a
major impact on the improvement of cancer treatment (Ros-
enberg et al., 1969). This compound is one of the key drugs
in the treatment of solid tumours such as germ-cell cancer,
ovarian cancer, bladder cancer and bronchial carcinoma
(Einhorn & Donahue, 1977; Wiltshaw & Kroner, 1976;
Soloway, 1978; Gralla et al., 1979). The severity of renal,
neuro, and gastrointestinal toxicity associated with cisplatin
administration encouraged the development of alternative
platinum compounds with a better therapeutic index. Cis-
diammine 1,1-cyclobutane-dicarboxylato-platinum (Carbo-
platin) has emerged as a leading analogue demonstrating a
highly reduced emetic and nephrotoxic effect while preserving
almost the same efficacy as cisplatin (Mangioni et al., 1989;
Bajorin et al., 1991). Myelosuppression is considered to be
the dose limiting toxicity of carboplatin. Complete cross-
resistance between the two drugs is however the rule and as a
consequence their spectrum of antitumour activity is com-
parable Canetta et al., 1988).
Lobaplatin (D-19466; 1, 2-diamminomethyl-cyclobutane-
platinum (II)-lactate) (Figure 1) was synthesised as a repre-
sentative of platinum derivatives of the third generation.
Lobaplatin showed a markedly higher antitumour effect in
vitro toward B16 melanoma and AH13s hepatoma compared
with cisplatin (Voegeli et al., 1990). This was also implied by
experiments performed in two cell lines and their cisplatin
resistant sublines. In one line, a small cell lung carcinoma cell
line (GLC4 and its resistant subline GLC4-CDDP), lobaplatin
showed full cross resistance, whereas in another line, a
human embryonal cancer cell line (Ntera2/D1 and its cis-
platin resistant subline tera-CP), lobaplatin demonstrated no
cross resistance (Meijer et al., 1991). In vivo, in mice bearing
the P388 leukaemia, administration of lobaplatin resulted in
a higher increase of life span compared with equitoxic doses
of cisplatin or carboplatin. In a cisplatin resistant P388,
tumour in which neither cisplatin nor carboplatin were able
to inhibit the proliferation after transplantation, the survival
of the animals was significantly prolonged by lobaplatin
(Voegeli et al., 1990). These preclinical data are suggestive for
the lack of cross-resistance of lobaplatin in a number of
platinum resistance tumour models.
After an intravenous (i.v.) bolus injection in mice a LD50
of 25.7 mg kg-' bodyweight and a LDIo of 16.0 mg kg-'
bodyweight was found. An i.v. dose near the LD,O in mice
did not cause changes in blood urea nitrogen level and only
minimal increases in urinary enzyme levels occurred. Com-
pared with equipotent doses of carboplatin, lobaplatin showed
comparable myelotoxic effects in mice. From these observa-
tions Lobaplatin was considered as a good candidate for
clinical evaluation with lack of preclinical serious nonhema-
tological toxicity and evidence of antitumour activity in a
number of cisplatin resistant tumours. A clinical phase I
study performed in Germany and employing a single-dose
i.v. bolus schedule indicated that thrombocytopenia was the
most common side effect of D-19466 (Fiebig et al., 1991).
The current study was undertaken to determine the max-
imum tolerated dosage (MTD) of lobaplatin given as a daily
i.v. bolus for 5 days and to characterise clinical toxicity.
Patients and methods
Twenty-seven patients entered this study between June 1990
and May 1991. All patients had histologically proven ad-
vanced cancers not amenable to conventional treatment. To
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Figure 1 Structure of lobaplatin (D-19466).
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be eligible for this study, patients had to fulfill the following
criteria: (a) age from 18 to 75 years; (b) an estimated life
expectancy of > 3 months; (c) a WHO performance status of
< 2; (d) complete recovery from all toxic effects from prior
treatments with a treatment free interval of at least 4 weeks;
(e) adequate bone marrow function (leucocyte count > 4 x
I09 1-' and platelet count > 100 x I09 1-1; (f) serum creati-
nine level < 135 tmol [` and a creatinine clearance (CRCL)
> 60 ml min-'; (g) alkaline phosphatase <1.5 times normal
and serum bilirubin < 26ymol 1-'; and (h) no coexisting
active medical problems. This protocol was approved by the
Medical Ethical Committee of the University Hospital Gron-
ingen, the Netherlands. Written consent was obtained from
all patients after being informed of the investigational nature
of this treatment.
Lobaplatin was supplied by ASTA Medica AG (Frankfurt,
Germany) in vials containing 20 mg white powder. The dose
of lobaplatin was dissolved in sterile water (2 ml 20 mg-')
and diluted in 100 ml 0.9% saline. In this study the proper
dose of lobaplatin was prepared daily and administered i.v.
in 10 min daily for 5 days. Patients were hospitalized on
lobaplatin dosing days. To ensure a sufficient diuresis on
these lobaplatin dosing days, patients received 1.5 1 saline
(0.45%) with glucose (0.45%) solution per 24 h, starting right
after the first lobaplatin administration. Courses were re-
peated every 4 weeks. No prophylactic anti-emetics were
given except if the patient experienced gastrointestinal tox-
icity > WHO grade 3.
The starting dosage of lobaplatin was based on animal
toxicology data and was one-tenth of the LDIo in mice. The
first three patients were entered at the lowest dose level. If
toxicity remained below grade 2 according to WHO criteria
(WHO handbook, 1978) the subsequent course in those same
patients was given at the next dose level, and escalation was
continued in that way. If toxicity exceeded grade 2, a de-
escalation to the previous dose level was performed. In case
of grade 2 toxicity the next course was given at the same
dose. This approach would limit the number ofpatients to be
treated at inactive dose levels, as all patients could reach the
ultimate dose. The chance that cumulative toxicity would
interfere with the dose finding was circumvented by entering
three to six new patients at the first dose level found to be
toxic (WHO grade 2). The initial dose levels for this study,
chosen with a modified Fibonacci search system (Hansen et
al., 1971), were 20-40-70-100mgm-2 (total dose per 5
days). After administering 11 courses of lobaplatin to the
first five patients entered in this study we became aware of
the possible relation between the hematological toxicity and
the CRCL of the patients at time of the lobaplatin adminis-
tration. Based on these data the starting dose of subsequent
patients for further dose escalation was adjusted to CRCL at
entrance of this study. Two 24-h urinary clearances were
measured within 1 week prior to treatment, the mean ofthese
two CRCL values was used to determine lobaplatin starting
dosage. Patients with a CRCL between 60 and 80 ml min'-
started at 30mgm2, with a CRCL between 81 and 100 ml
min-' started at 40 mgm2 and patients with a CRCL above
100 ml min-' started at 70 mgm-2 Lobaplatin. Additional
dose levels of lobaplatin added to the initial escalation
scheme were 30, 55, and 85 mg m-2. Escalation and de-
escalation methods remained the same as mentioned above.
The MTD was defined as the dose at which any parameter
reached WHO grade 3 or 4 toxicity in three patients.
During each 28 day course complete blood cell count,
electrolytes, liver and renal function, and glucose were
measured on each treatment day and on day 14, 21, and 28.
Twenty-four-hour urinary creatinine clearances were per-
formed twice before study entry, twice prior to each loba-
platin course, on each treatment day and on day 14 of each
course. The CRCL before study entry and during lobaplatin
treatment were done while patients were hospitalised to
ensure complete urine collection. ECG and chest X-rays were
done before each course of lobaplatin.
To be evaluable for response the patient with measurable
disease had to receive at least two courses of lobaplatin.
Tumour evaluation were performed at entry and after every
two treatment cycles. A complete response (CR) was defined
as a disappearance of all evidence of the tumour and no
development of new lesions for at least 4 weeks. A partial
response (PR) was defined as a decrease of at least 50% in
the sum of the products of the largest perpendicular diam-
eters of all measurable lesions. Stable disease meant a de-
crease within 50% or an increase of less than 25% in any
measurable lesions. Progressive disease was defined as an
increase of more than 25% of the lesions or the occurrence
of any new lesions.
In six patients urine samples were collected every hour
during the first 4h after the first daily dose of lobaplatin,
thereafter at time of voiding and stored as pooled 4 h collec-
tions. Samples were stored at - 20°C until analysed. Plati-
num concentration in urine samples was determined by
flameless atomic absorption spectrometry (AAS) (13). The
amount of platinum was determined using a model AA1275
atomic absorption spectrophotometer with a GTA95 graphite
furnace and autosampler unit (Varian Techtron Pty. Ltd,
Mulgrave Victoria, Australia). Absorption was measured at
265.9 nm with a spectral band-with of 0.5 nm and deuterium
background correction. Urine samples were analysed after
3:1 dilution in a solution of 23 Lauryl Ether 0.3%. A cali-
bration curve was made in the same organic matrix, the limit
of detection was 0.1 mg platinum -'.
Statistics
Regression analysis in this study was calculated by the
method of least squares. Statistical analysis was performed
with the Student's t-test. Only two-tailed P-values <0.05
were considered to be significant.
Results
The characteristics of patients entered in this phase I trial are
outlined in Table I. The 27 patients received 72 courses
(median 2 range: 1 to 7). Administered number of courses
lobaplatin on different dose levels are given in Table II. All
patients were evaluable for toxicity and 20 also for response.
Toxicity
Thrombocytopenia was dose limiting in all patients. The
degree of thrombocytopenia was related to dose given and
CRCL at time of administration, therefore three different
renal function cohorts were introduced after the first five
patients were entered. For these renal function cohorts differ-
ent MTDs were found. Details of hematological toxicity are
summarised in Tables III and IV. Three out of five patients
with a CRCL between 60 and 80 ml min experienced grade
3/4 thrombocytopenia at 40 mg m-2. In one patient this was
accompanied by a grade 3 leukocytopenia. This dose level
was considered to be maximal tolerable for patients with a
CRCL between 60 and 80 ml min-'. At 70 mg m-2 throm-
bocytopenia grade 3/4 occurred in six out of seven patients
with a CRCL between 81 and 100 ml min-', and was there-
fore the maximum tolerable dose. In one patient this was
accompanied by a grade 3 leukocytopenia. In patients with a
CRCL above lOOml min-' 85 mg m2 was found to be the
MTD. Grade 4 thrombocytopenia was encountered in three
out of four patients treated at this dose level, accompanied in
two by a grade 3 leukocytopenia. Twenty-three of all patients
reached the maximum administered dose level during their
first or second course of lobaplatin. All except three patients
were pretreated with chemotherapy, so the influence of
previous treatment on hematologic toxic effects of lobaplatin
could not be evaluated. The median time to platelet count
nadir was 21 days (range 14 to 28), the median time to
leukocyte count nadir was 19 days (range 6 to 28). The
median time to recovery of the platelet counts was 7 days
(range 2 to 18), the median time to recovery of leucocyte
counts was 7 days (range 1to 18). The blood count recovery398 J.A. GIETEMA et al.
was not different when the first course was compared with
the second or third course. Six of 23 patients receiving multi-
ple courses of lobaplatin required postponement of a course,
all because of not fully recovered leukocyte count. Patients
escalating to higher dose levels had no more myelosuppres-
sion than new patients entered at these levels. From patients
treated with three or more courses lobaplatin on the same
Table I Clinical characteristics of
lobaplatin
Median age (range)
Male/Female
Performance status (WHO)
0
1
2
Primary site
Colon carcinoma
Ovarian carcinoma
Soft tissue sarcoma
Gastric carcinoma
Endometrial carcinoma
Testicular carcinoma
Renal cell carcinoma
Carcinoma of the papilla of Vater
Bladder carcinoma
Adeno carcinoma of unknown
primary origin
Previous treatment
Chemotherapy
Radiotherapy
Radiotherapy + Chemotherapy
Immunotherapy
None
Prior treatment with cisplatin or carboplatin
27 patients treated with
Number ofpatients
52 (26-68) years
11/16
7
9
11
7
7
4
2
2
1
10
Table II Administered number of courses lobaplatin at different
dosages (total dose over 5 days)
Number of patients Number of courses
Dose level Administered as course number
(mgm-2) Total 1 2 > 3
20 5 5 4 1 0
30 5 11 3 1 7
40 11 16 5 6 5
55 13 18 4 9 5
70 14 16 9 2 5
85 4 4 1 2 1
100 2 2 0 2 0
Table III Hematologic toxicity after lobaplatin treatment
Leucopenia
Dose (no. patients/ WHO grade
(mgm-2) no. courses) 0 1 2 3 4
CRCL 60-80mlmin-'
20 (3/ 3) 2 1 - - -
30 (4/10) 3 4 3 -
40 (5/ 9) - 3 4 2 -
55 (2/ 2) - - 2 - -
70 (1/ 1) - - I -
CRCL 81-100mlmin-'
30 (1/ 1) - 1 -
40 (3/ 4) 1 1 2 -
55 (7/10) 3 2 4 1 -
70 (7/ 7) - 2 4 1 -
CRCL >lOOmlmin-'
20 (2/ 2) 2 - - - -
40 (3/ 3) 1 2 - - -
55 (5/ 6) 4 1 1
70 (6/ 8) 2 3 3 -
85 (4/ 4) - 2 - 2
100 (2/ 2) - 2
Table IV Hematologic toxicity after treatment with lobaplatin
Thrombocytopenia
Dose (no. patients! WHO grade
(mgM-2) no. courses) 0 1 2 3 4
CRCL 60-80mlmin-'
20 (3/ 3) 2 1 - -
30 (4/10) 4 1 5 - -
40 (5/ 9) - 2 3 2 2
55 (2/ 2) - - 1 1
70 (1/ 1) - - - 1
CRCL 81-100 ml min-'
30 (1/ 1) 1 -
40 (3/ 4) 3 1 - -
55 (7/10) 4 4 1 1 -
70 (7/ 7) - 1 - 1 5
CRCL > 100 mlmin-'
20 (2/ 2) 2 -
40 (3/ 3) 3 -
55 (5/ 6) 5 - 1 -
70 (6/ 8) 2 1 3 2 -
85 (4/ 4) - - I - 3
100 (2/ 2) - - 2
dose level, only those receiving 55 mg m-2 or more, experi-
enced some signs of cumulative toxicity predominantly
affecting the platelets. One patient with a renal cell car-
cinoma with multiple lung metastases experienced hemoptysis
during thrombocytopenia from lobaplatin. Eleven patients
received preventive platelet transfusions at the time they had
a WHO grade 4 thrombocytopenia. Of 23 patients receiving
two or more courses, nine patients developed a symptomatic
anemia (WHO grade 2) requiring a red blood cell trans-
fusion. This toxicity was not clearly related to dose level.
The degree of myelosuppression occurring after lobaplatin
depended on dose and renal function. This was illustrated by
different MTD's in the three CRCL cohorts. As throm-
bocytopenia was dose limiting in all patients, we analysed the
relation between platelet nadir and CRCL at different dose
levels. The platelet nadir was defined as percentage of
pretreatment platelet count:
Pretreatment platelet count
Percentual platelet nadir= x 100
Platelet nadir count
The CRCL used was the mean CRCL (mlmin-') of 2 days
before a course and on the 5 dosing days of lobaplatin. Such
analysis was performed at two intermediate dosages 40 and
70 mg m2 . Of the first 12 consecutive patients treated with
40 or 70 mg m-2 lobaplatin during their first or second
course, 14 cycles were used (eight cycles at 40 mg m2, six
cycles at 70mgm2). This analysis produced for the two
different dose levels of lobaplatin two nearly parallel regres-
sion lines described by the equations:
40 mg m-2: Percentual platelet nadir = 0.81 x CRCL-14.77
70 mgm-2: Percentual platelet nadir = 0.71 x CRCL-58.39
These two relationships proved to be linear, with correlation
coefficients of 0.79 and 0.98, respectively. On basis of these
equations the following equation was derived to predict the
percentual platelet nadir in a patient with a given CRCL and
dose lobaplatin (total dose over 5 days):
Percentual platelet nadir = 0.76 x CRCL (mlminm) -
(1.45 x dose (mg m-2)) + 43.38
The potential utility of this equation was tested in the first
two courses at dose levels 30 to 85 mg m-2 in 20 patients (28
courses), excluding the courses used for deriving the equa-
tions. A significant relationship was demonstrated between
the observed percentual platelet nadir and the predicted
percentual platelet nadir (r=0.82; P<0.001) (Figure 2).
Non hematological toxicity was confined to mild nausea
and emesis (Table V). Patients tended to experience grade 2
nausea when they reached their maximum tolerable dose
according to the renal function cohort they belonged to.PHASE I STUDY OF LOBAPLATIN 399
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Figure 2 Correlation between observed and predicted percentual
platelet nadir (% of pretreatment platelet count) with the equa-
tion in the first two courses lobaplatin on dose levels 30-85
mgm-2 (28 courses administered to 20 patients excluding the
courses used for deriving the equation). (r = 0.82, P< 0.001).
Table V Non-hematological toxic effects of lobaplatin
Nausea and vomiting
Dose WHO grade
(mgm2) no. ofpatients 0 1 2 3 4
20 5 4 1 - -
30 5 4 - 1 -
40 11 5 2 4 - -
55 13 6 4 2 1 -
70 14 4 5 5 - -
85 4 1 2 1 -
100 2 - - 2 - -
Platinum pretreated 10 - 1 8 1
Platinum ignorant 17 7 7 3 -
Patients pretreated with a platinum compound experienced
more often nausea > WHO grade 1 than platinum naive
patients (Table V). The gastrointestinal adverse toxic effects
of lobaplatin could be completely abrogated by the 5-HT3
receptor antagonist ondansetron. Antiemetics were admini-
stered to nine patients, only after they experienced WHO
grade 2 nausea and vomiting. No changes in CRCL or serum
creatinine were observed during treatment with lobaplatin. In
patients who received multiple courses lobaplatin (n = 23),
the mean CRCL before the first and after the last treatment
course was 101 ± 28 and 99 ± and 24 ml min-', respectively
(P>0.3); the mean serum creatinine before the first and after
the last course was 74 ± 17 and 80 ± 18tsmol 1', respectively
(NS). One patient with a colon carcinoma with liver metas-
tases and progressive disease during treatment, developed
proteinuria (maximal 3 g per 24 h) during her second course.
This selective proteinuria did not alter after the third and last
course. No other signs of renal toxicity were observed during
this trial. One patient with a soft tissue sarcoma of the
stomach with regional progression in the liver developed
during her third course of lobaplatin liver function distur-
bances (WHO grade 2) with an elevation of alkaline phos-
phatase and T-glutamyl transferase without signs of tumour
progression. The liver function disturbances disappeared after
lobaplatin was stopped, and may therefore be related to the
trial drug. No other signs of hepatic toxicity were observed.
None of the patients developed alopecia. There was no evi-
dence of neurotoxicity during this study. At entry four pa-
tients had paresthesias due to previous cisplatin treatment,
none of them experienced a deterioration of the paresthesias
(three of them received three or more courses of lobaplatin).
No signs of ototoxicity were observed although audiograms
were not done systematically. No cardiac, or pulmonary
toxicity was encountered in this regimen.
Tumour response
In the 20 evaluable patients there were two responses, one
PR and one CR (Table VI). Both patients had ovarian
cancer. The patient with PR of a supraclavicular lymph node
had failed to respond to initial chemotherapy with carbo-
platin and cyclophosphamide, and had progressive disease
during subsequent treatment with intraperitoneal cisplatin.
Response duration was 2 months and was accompanied by a
decrease of the tumour marker CA-125 (measured with an
enzyme-linked immunosorbent assay; Abbott, Chicago, IL)
from 3,300 to 930 U -'. The patient with the CR of an
abdominal lesion, measurable with ultrasound, accompanied
by normalisation of an initial elevated CA-125. She was
pretreated with cisplatin and cyclophosphamide during which
a complete response was obtained, after second line treat-
ment with intraperitoneal cisplatin she achieved a PR (dura-
tion: 18 months). The complete response on lobaplatin now
lasts 8 + months. Two patients with ovarian cancer had
stable disease, in one this was accompanied by a decrease of
the CA-125 (Pretreatment: 9,800 U 1-1, after four courses
lobaplatin: 525 U1`). The other two had progressive disease.
Pharmacokinetics
The kidney was the major route of excretion. After 4 h most
of the platinum injected had been excreted in the urine (mean
91.5%; range 66 to 113) (Figure 3). The pattern of excretion
was similar at different dose levels tested. No correlation
could be detected between CRCL and the amount of plat-
inum excreted in the urine. In three patients urinary excretion
of platinum was measured both on day 1 and day 5 of
lobaplatin administration. In all three cases measurements on
day 5 were similar with those on day 1.
Table VI Therapeutic effects of lobaplatin
Number ofpatients
Evaluable for responsea 20/27
Progressive disease 13
Stable disease 5
Partial remission 1
(ovarian cancer: 2 months)
Complete remission 1
(ovarian cancer: 8 + months)
aMeasurable disease and at least two courses of lobaplatin.
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Figure 3 Urinary excretion of platinum by six patients injected
with lobaplatin. Each line represents an individual patient.
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Discussion
Lobaplatin was introduced in clinical trials because of its
limited toxicity while in preclinical tumour systems it showed
promising antitumour activity in cell lines and xenografts
resistant to cisplatin (Voegeli et al., 1990; Meijer et al., 1991).
The results of this clinical phase I trial indicate that some of
these expectations may be fulfilled. Lobaplatin is a well
tolerated drug with predictable dose-related side effects.
Careful monitoring of toxicity revealed after entering five
patients that the dose-limiting toxicity was thrombocytopenia
and that it was related to CRCL. Dose limiting throm-
bocytopenia occurred at different dosages lobaplatin in the
three distinct CRCL cohorts that patients were entered into:
60-80, 81-100, and >I00 mlmin-', and were 40, 70, and
85 mg m-2, respectively. Thrombocytopenia was marked but
short of duration. The nausea and vomiting in this Loba-
platin daily times 5 schedule was mild, dose related and
predominantly occurred in patients, pretreated with cis- or
carboplatin. No decreases in renal function expressed in
creatinine clearance were detected in any of the patients
treated with Lobaplatin, therefore the drug is probably not
nephrotoxic. Overall, the toxicity profile of Lobaplatin ob-
served in this phase I trial resembles that of a carboplatin
daily for 5 days schedule with hematological toxicity being
dose limiting (Van Echo et al., 1984; Rozencweig et al.,
1983).
Egorin et al. (Egorin et al., 1984) found that the percen-
tage reduction in platelet counts induced by carboplatin was
correlated with the CRCL. With this observation they de-
rived an equation with which the platelet nadir could be
predicted. Furthermore Calvert et al. (Calvert et al., 1989)
saw predictable hematological toxicity of carboplatin based
on target area under the curve (AUC) and 51CrEDTA
clearances in a prospective study. Another investigational
platinum-complex 254-S was also found to induce a reduc-
tion in platelet counts that was related to renal function
(Sasaki et al., 1990). The rationale behind these relationships
comes from the fact that the kidney is the major route of
excretion of these platinum compounds. In the present study
with a platinum compound also primarily excreted by the
kidney we were able to establish a significant relation
between the percentual platelet nadir count and the CRCL.
This enabled us to derive an equation to predict the percen-
tual platelet nadir (percentage of pretreatment platelet
count). Testing this equation in 28 first or second courses of
lobaplatin revealed a good correlation between the observed
and predicted percentual platelet nadir. Because most of the
patients studied in deriving this formula were pretreated with
chemotherapy, we were not able to make a correction, such
as described by Egorin et al. (Egorin et al., 1984), for
chemotherapy naive patients. Rearrangement of this relation-
ship yielded the following equation with which to calculate
lobaplatin dosages (total dose over 5 days) for pretreated
patients with given CRCL's and desired platelet nadirs.
Dose Lobaplatin (mg m-2) = 0.69 x {0.76 x CRCL -
platelet nadir desired
(pretreatment platelets x 100) + 43.38)
Application of this equation is only valid when the CRCL is
in the range studied by us (between 60 and 155 ml min-1).
The potential utility of this equation has to be further
evaluated in a prospective study. Its usefulness in patients
with a CRCL below 60 ml min' has also yet to be estab-
lished.
Urinary excretion of Lobaplatin was remarkably rapid
with 91.5% (s.e. ± 7.9) of the platinum dose being excreted
within 4 h. This was much faster than the excretion of
platinum after administration of carboplatin (25 to 30%
within 4 h) in a comparable regimen (Egorin et al., 1984).
One of the most promising results from this trial were two
responses seen in six evaluable patients with ovarian cancer.
The patient with a PR could be marked as clinical completely
resistant to platinum, with refractory disease after first line
carboplatin based chemotherapy and tumour progression
during second-line cisplatin based therapy. The second pa-
tient had shown partial resistance on her second platinum
line, but had a prolonged complete remission on Lobaplatin.
Therefore this study provides clinical evidence that Loba-
platin might at least in part be non-cross resistant with
cisplatin and carboplatin. Further trials with lobaplatin are
therefore warranted.
Based on the current trial, the recommended dose of
lobaplatin for phase II studies with a daily times five bolus
infusion depends on renal function; CRCL 60-80 ml min-':
30 mgm-2; CRCL 81-100mlmin-': 55 mgm-2; CRCL
> 100 ml min-': 70mgm2.
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